ArticleJournal of experimental & clinical cancer research : CR2018

The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma.

Hye Jeong Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.